

# A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	UCB Biopharma SRL
<b>Enrollment</b>	90 participants

## Key Eligibility Criteria

---

### Inclusion (16)

- Cohort A and Cohort B
- Study participant must be at least 18 years of age inclusive at the time of signing the Informed Consent Form (ICF)
- Study participant must have:
- Cohort A and Cohort B: Plaque psoriasis (PSO) diagnosed for at least 6 months prior to the Screening Visit
- Cohort B only: In addition to the criteria specified above, study participant has a documented diagnosis of adult-onset psoriatic arthritis (PsA) and meets the CASPAR classification criteria for at least 6 months prior to Screening for active PsA and must have e1 tender joint count (TJC) out of 68 and e1 swollen joint count (SJC) out of 66 at Screening or up to 3 months before Screening (documented evidence)

... and 11 more (see full listing online)

### Exclusion (20)

- Cohort A and Cohort B
- Study participant has a form of PSO other than plaque type (eg, pustular, erythrodermic and guttate PSO, or drug induced PSO)
- Study participant has an active infection or history of infection(s) as follows:
- Any active systemic infection within 14 days prior to Baseline
- A serious infection, defined as requiring hospitalization or intravenous anti-infective(s) within 2 months prior to the Baseline Visit

... and 15 more (see full listing online)

## Locations (16 total)

---

Ps0039 50140, Birmingham, Alabama, United States  
Ps0039 50162, Fountain Valley, California, United States  
Ps0039 50642, Santa Monica, California, United States

... and 13 more locations